Recent changes
GovPing tracks 141 sources for this role out of 2,348 total sources on GovPing, covering Guidance, Enforcement, Rule, Notice, and Consultation instruments. There were 722 changes in the last 7 days.
Health Canada issued a Type I recall for nitrous oxide chargers sold by DOODELZ, Gold Whip, and Whip-it! brands without market authorization, while the UK VMD called for a Class II recall of Zoetis's Scabigard Suspension for cutaneous administration. FDA classified Draeger's Atlan A350 anesthesia workstations as a Class I recall due to potential piston ventilator failure, and Morovan recalled approximately 4,000 units of Gel Nail Polish Remover for methylene chloride and chloroform contamination.
Blaine Labs Recalls Revitaderm and Tridergel Wound Care Gel Due to Microbial Contamination
Blaine Labs, Inc. has voluntarily recalled three lot numbers of Revitaderm and Tridergel Wound Care Gel products (BL3608, BL3435, BL3525) distributed nationwide to healthcare providers due to contamination with Lysinibacillus fusiformis, an environmental spore-forming bacterium. The contaminated 1 oz. and 3 oz. antiseptic wound gels pose infection risk to patients with open wounds, compromised skin barriers, or weakened immune systems.
Recombinant Fusion Polypeptides Enable Bacteroides Cargo Secretion
Recombinant Fusion Polypeptides Enable Bacteroides Cargo Secretion
Universal Peptide/MHC Complexes with Engineered Disulfide
The USPTO published patent application US20260097105A1 by Nikolaos SGOURAKIS for synthetic major histocompatibility complex (MHC) molecules featuring engineered disulfide linkages connecting heavy and light chains. The invention covers systems, formulations, and methods for generating universal peptide/MHC complexes using structure-guided modeling and design. Application No. 19114130 was filed September 28, 2023, with CPC classifications including A61K 39/001188, A61K 39/385, C07K 14/4748, and C07K 14/70539.
Flavivirus Vaccine Polynucleotides Inducing Protective CD8+ T Cell Immunity
USPTO published patent application US20260097108A1 by inventors Charneau et al. disclosing recombinant polynucleotides encoding non-structural antigens from Dengue virus (DENV), Zika virus (ZIKV), and Yellow Fever virus (YFV) designed to elicit protective CD8+ T-cell immune responses. The application covers polyepitope fusion polypeptides and lentiviral vectors for flavivirus vaccine development.
Erythroid Lineages from Pluripotent Cells
USPTO published patent application US20260097074A1 by Dhvanit Shah disclosing methods for generating hematopoietic lineages including erythroid progenitor cells, progenitor erythroblasts, and erythroid cells from human induced pluripotent stem cells (iPSCs) for cell therapy applications. The application covers efficient ex vivo processes for developing these lineages and isolated cell compositions produced by the methods.
Cell Behavior Control Methods Without Genetic Modification
USPTO published patent application US20260097078A1 by inventors Victor TETS and Georgy TETS covering products and methods for managing cell behavior, cell memory, and erasure of cell memory without genetic modification. The application relates to therapeutic, diagnostic, agricultural, and biomanufacturing applications. The invention distinguishes itself from prior art by enabling control of cellular properties without mutagens, gene introduction, or environmental condition changes.
Removing Endogenous TCR Chains for Enhanced TCR-Based Immunotherapies
USPTO published patent application US20260097079A1 by Khosravi Maharlooei et al. disclosing methods for treating diseases using adoptive cell therapy with modified lymphocytes having inactivated endogenous TCRα and TCRβ chains. The application covers compositions and methods for enhanced TCR-based immunotherapies.
Method to Change Tumor Associated Macrophage Polarization Using Magnetosomes and Radiation
USPTO published patent application US20260097075A1 by Université Paris Cité for a method to change tumor-associated macrophage polarization by exposing macrophages to magnetosomes and radiation. The invention aims to shift macrophages from M0 or Mi polarization to Mj polarization for potential cancer immunotherapy applications.
Modified Gamma Delta T Cells for Cancer Therapy
USPTO published patent application US20260097077A1 for a method of treating cancer using gamma delta T cells modified with XBP1 gene or protein inhibitors. The modified T cells demonstrate enhanced antitumor activity in tumor microenvironments with endoplasmic reticulum stress. Inventors are Minkyung Song, Hocheol Shin, and Ji Yun Park, with application filed September 4, 2025.
Exosomes from Mesenchymal Stem Cells for Alzheimer's Treatment
USPTO published patent application US20260097080A1 covering exosomes isolated from mesenchymal stem cells for reducing inflammation and treating Alzheimer's disease. The application claims exosomes exposed to conditioned media with microglial cells in the presence of LPS or beta-amyloid oligomer. This is a publication of a pending application, not a granted patent.
Get daily alerts for pharma & life sciences
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
720 changes in last 7 days
Latest high priority updates
141 official sources tracked
Frequently asked questions
What does this feed cover?
FDA warning letters, novel drug approvals, drug shortage notices, ICH guideline updates, USP notices, EMA news, DEA scheduling decisions, and TGA/WHO standards.
Who is this for?
Regulatory affairs professionals, pharmacovigilance teams, and medical affairs groups at pharma companies and CROs who need to track FDA and EMA actions.
How often is this updated?
GovPing checks source pages multiple times daily. FDA warning letters and drug approvals typically appear within hours of publication.
Does this cover EMA and international regulators?
Yes. We monitor the EMA, ICH, WHO, TGA (Australia), and other international health authorities alongside FDA.
How is this different from AgencyIQ?
AgencyIQ is a full FDA intelligence platform. GovPing is a free feed of the FDA, EMA, and ICH source pages where warning letters, approvals, drug shortages, and guidance are first published - AI-summarized with attention-level ratings on every change.
Is GovPing free?
Yes. GovPing is free, and always will be. We believe government regulatory data should be accessible to everyone. For custom monitoring of pages we don't cover yet, Changeflow starts at $99/mo.
Need to monitor something else?
GovPing covers the common sources. For niche pages specific to your team, add custom URL monitoring with Changeflow.
Get Pharma & Life Sciences alerts
Daily digest of pharma & life sciences regulatory changes. AI-summarized, no noise.
Free. Unsubscribe anytime.